| 28.24 0 (0%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Intersect ENT, Inc. is a medical technology firm focused on ear, nose, and throat (ENT) solutions, operating within the United States. Its product portfolio includes: PROPEL, PROPEL Mini, and PROPEL Contour: These are steroid-eluting implants. PROPEL is designed to maintain the patency of surgically enlarged sinuses, while PROPEL Mini targets patients undergoing frontal sinus procedures. PROPEL Contour specifically addresses the frontal and maxillary sinus ostia, or passages, within the dependent sinuses. SINUVA: Another steroid-releasing implant, intended for patient care in a clinical office environment. VENSURE Navigable and Stand-alone balloon: A sterile, single-use balloon device that facilitates access to and treatment of the frontal, sphenoid, and maxillary ostia in adult patients via a trans-nasal method. CUBE Navigation System: A digital guidance system offering high-accuracy navigation for ENT and associated skull-base surgical interventions. The company, originally established as Sinexus, Inc. in 2003, rebranded to Intersect ENT, Inc. in November 2009. Its corporate headquarters are located in Menlo Park, California.
Wed, 11 Mar 2026
Google acquires Intersect Power for $4.75bn - Power Technology
Mon, 09 Feb 2026
Intersect Power files to develop data center in Texas - Data Center Dynamics
Mon, 22 Dec 2025
Alphabet to acquire data center and energy infrastructure company Intersect - CNBC
Sun, 15 May 2022
Medtronic Completes Acquisition of Intersect ENT - respiratory-therapy.com
Fri, 13 May 2022
Medtronic completes Intersect ENT acquisition - Drug Delivery Business
Wed, 11 May 2022
Medtronic completes Intersect acquisition following FTC order - MedTech Dive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|